ATE414537T1 - Antikörper enthaltende stabilisierte zubereitungen - Google Patents

Antikörper enthaltende stabilisierte zubereitungen

Info

Publication number
ATE414537T1
ATE414537T1 AT02762901T AT02762901T ATE414537T1 AT E414537 T1 ATE414537 T1 AT E414537T1 AT 02762901 T AT02762901 T AT 02762901T AT 02762901 T AT02762901 T AT 02762901T AT E414537 T1 ATE414537 T1 AT E414537T1
Authority
AT
Austria
Prior art keywords
preparations containing
containing antibodies
stabilized preparations
stabilized
acetyltryptophan
Prior art date
Application number
AT02762901T
Other languages
English (en)
Inventor
Tadao Yamazaki
Hiroko Konishi
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE414537T1 publication Critical patent/ATE414537T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT02762901T 2001-08-29 2002-08-29 Antikörper enthaltende stabilisierte zubereitungen ATE414537T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001258988 2001-08-29

Publications (1)

Publication Number Publication Date
ATE414537T1 true ATE414537T1 (de) 2008-12-15

Family

ID=19086420

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02762901T ATE414537T1 (de) 2001-08-29 2002-08-29 Antikörper enthaltende stabilisierte zubereitungen

Country Status (6)

Country Link
US (1) US7682608B2 (de)
EP (1) EP1428537B1 (de)
JP (1) JP4342941B2 (de)
AT (1) ATE414537T1 (de)
DE (1) DE60229961D1 (de)
WO (1) WO2003018056A1 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US20070184050A1 (en) * 2003-12-25 2007-08-09 Kirin Beer Kabushiki Kaisha Stable water-based medicinal preparation containing antibody
WO2008068885A1 (ja) * 2006-11-30 2008-06-12 Sanyo Chemical Industries, Ltd. 凍結乾燥用保護剤及び生理活性物質の製造方法
MX2009007406A (es) * 2007-01-09 2010-01-25 Wyeth Corp Formulaciones de anticuerpo anti-il-13 y usos de las mismas.
CA2687291A1 (en) * 2007-05-16 2008-11-20 Ktb Tumorforschungsgesellschaft Mbh Low-viscous anthracycline formulation
JP4812807B2 (ja) * 2007-06-27 2011-11-09 三洋化成工業株式会社 タンパク質含有水溶液安定化剤及びタンパク質含有水溶液の安定化方法
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US20110086163A1 (en) * 2009-10-13 2011-04-14 Walbar Inc. Method for producing a crack-free abradable coating with enhanced adhesion
TWI606840B (zh) 2010-11-11 2017-12-01 艾伯維生物技術有限責任公司 具有增進高濃度之抗-ＴＮＦα抗體之液體調配物
PT2968466T (pt) * 2013-03-13 2018-10-22 Hoffmann La Roche Formulações de oxidação reduzida
US20140314778A1 (en) 2013-03-13 2014-10-23 Genentech, Inc. Formulations with reduced oxidation
CN104977408B (zh) * 2015-06-15 2016-09-14 暨南大学 一种筛选分泌特异性单克隆抗体杂交瘤细胞的方法与应用
EP3397243A1 (de) * 2015-12-30 2018-11-07 H. Hoffnabb-La Roche Ag Verwendung von tryptophanderivaten für proteinformulierungen
AR124914A1 (es) 2021-02-18 2023-05-17 Mitsubishi Tanabe Pharma Corp Nuevo anticuerpo anti-pad4

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5157113A (en) 1987-08-10 1992-10-20 Miles Inc. Removal of nucleic acids from monoclonal antibody preparations
ES2045027T3 (es) 1987-08-10 1994-01-16 Miles Inc Igm purificadas.
CA2049342A1 (en) * 1989-03-27 1990-09-28 Sally Bolmer Formulations for stabilizing of igm antibodies
JPH0768137B2 (ja) 1989-06-15 1995-07-26 株式会社ミドリ十字 アルブミン製剤及びその製法
TWI240627B (en) 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
EP0852951A1 (de) 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AUPO871997A0 (en) * 1997-08-25 1997-09-18 Csl Limited Dried biologically or therapeutically active preparations
DK1069185T3 (da) * 1998-04-03 2011-06-27 Chugai Pharmaceutical Co Ltd Humaniseret antistof mod human vævsfaktor (TF) og fremgangsmåde til at konstruere humaniseret antistof
AU2001236005A1 (en) * 2000-02-29 2001-09-12 Chugai Seiyaku Kabushiki Kaisha Preparations stabilized over long time

Also Published As

Publication number Publication date
US7682608B2 (en) 2010-03-23
US20040213785A1 (en) 2004-10-28
EP1428537B1 (de) 2008-11-19
JPWO2003018056A1 (ja) 2004-12-09
WO2003018056A1 (fr) 2003-03-06
JP4342941B2 (ja) 2009-10-14
DE60229961D1 (de) 2009-01-02
EP1428537A4 (de) 2005-11-09
EP1428537A1 (de) 2004-06-16

Similar Documents

Publication Publication Date Title
ATE414537T1 (de) Antikörper enthaltende stabilisierte zubereitungen
DK2316852T3 (da) Stabiliserede enkeltdomæne-antistoffer
WO2004041865A3 (en) Stabilized single domain antibodies
WO2004101739A3 (en) Methods for chemically synthesizing immunoglobulin chimeric proteins
DE60329489D1 (de) Fusionsproteine humanisierter g250-spezifischer antikörper sowie verwendungen davon
CY1114164T1 (el) Μεθοδος ελεγχου της δραστικοτητας ανοσολογικα λειτουργικου μοριου
ATE485835T1 (de) Antikörper enthaltende pharmazeutische lösungen
ATE316982T1 (de) Mehrere zytokin-antikörper komplexen
DE69333800D1 (de) Thioether enthaltende Konjugate
DK1025227T3 (da) Humane TOLL-homologer
ATE223229T1 (de) Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren
ATE348852T1 (de) Ph-wert-geregeltes polyamidpulver
IL172729A0 (en) Reagents and methods for the formation of disulfide bonds and the glycosylation of proteins
DE60332711D1 (de) Neue insektizide proteine von bazillus thuringiensis
ITBO20010545A0 (it) Articolo per la coltivazione di specie orticole
DE60322613D1 (de) Frostschutzproteine aus Basidiomyceten
WO2003038041A3 (en) Il-4 mutein proteins, antibodies, compositions, methods and uses
ATE403670T1 (de) Rückgefaltetes membranprotein in monodisperser form
DK1456404T3 (da) Fremgangsmåde til at bestemme difibrotids biologiske aktivitet
DK0501215T3 (da) Fusionsproteiner indeholdende monoklonalt antistof, linker og beta-glucuronidase til pro-drug-aktivering, deres fremstillin
DE60012713D1 (de) Durch xanthurensäure modifizierte proteine
ATE250021T1 (de) Hydroxycyclopentanone
DE60124230D1 (de) Pseudovirus-partikel des rotavirus und ihre verwendung als vektoren für proteine und nukleinsäuren
WO2003057821A3 (en) Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
AU2002245255A1 (en) Regulation of target protein activity through modified proteins

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties